Pancreatic Cancer Research

ResearcherCornell UniversityActive in the last 2 years

William R. Jarnagin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-1635-5768; OpenAlex author ID A5042440032. Sources: ClinicalTrials.gov.

Their work

Papers
52 (first author 2, last author 4)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
152
Papers, trials and grants by year

2011: 2 papers · 2012: 6 papers · 2013: 2 papers · 2014: none · 2015: 2 papers, 1 trial · 2016: 2 papers · 2017: 2 papers · 2018: 4 papers · 2019: 1 paper · 2020: 1 paper · 2021: 3 papers · 2022: 10 papers · 2023: 3 papers · 2024: 4 papers · 2025: 8 papers · 2026: 2 papers

Papers 50 of 52

  1. Maximal Ablative Irradiation Because of Encasement for Patients With Locally Advanced Pancreatic Cancer: A Nonrandomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2026.2988↗
  2. Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial. Co-author DOI 10.1038/s41591-026-04299-5↗
  3. Influence of biologic sex and obesity on liver recurrence and survival in patients undergoing upfront surgery for pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.70088↗
  4. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08508-4↗
  5. Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival. Co-author DOI 10.1038/s41591-024-03362-3↗
  6. Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort. Co-author DOI 10.1093/jnci/djae269↗
  7. Genome-based classification of pancreatic acinar cell carcinoma reveals similarities to KRAS wild-type PDAC. Last author DOI 10.1186/s12967-025-07381-7↗
  8. Impact of Financial Toxicity on Treatment Adherence and Quality of Life in Pancreatic Cancer. Co-author DOI 10.1200/op-24-00528↗
  9. Outcomes in Locally Advanced Pancreatic Cancer After Induction Ablative Radiation Therapy and Resection. Co-author DOI 10.1245/s10434-025-17199-8↗
  10. Radiomics in sporadic microsatellite instable, mismatch repair deficient and Lynch syndrome-associated pancreatic ductal adenocarcinoma: a pilot study. Co-author DOI 10.3389/fonc.2025.1584167↗
  11. Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer. Co-author DOI 10.1016/j.ccell.2024.08.002↗
  12. Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer. Co-author DOI 10.1038/s41591-024-03075-7↗
  13. Treatment Patterns and Outcomes in Pancreatic Cancer: A Comparative Analysis of Ontario and the USA. Co-author DOI 10.1245/s10434-023-14375-6↗
  14. Salvage Ablative Radiotherapy for Isolated Local Recurrence of Pancreatic Adenocarcinoma following Definitive Surgery. Co-author DOI 10.3390/jcm13092631↗
  15. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Co-author DOI 10.1038/s41586-023-06063-y↗
  16. Registration-based biomarkers for neoadjuvant treatment response of pancreatic cancer via longitudinal image registration. Co-author DOI 10.1117/1.jmi.10.3.036002↗
  17. Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-22-3089↗
  18. Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma. Last author DOI 10.1002/jso.26735↗
  19. Development and validation of the Massachusetts General Hospital/Memorial Sloan Kettering nomogram to predict overall survival of resected patients with pancre… Co-author DOI 10.1016/j.surg.2022.05.024↗
  20. BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signali… Co-author DOI 10.1038/s41467-022-34081-3↗
  21. FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium. Co-author DOI 10.1093/jnci/djac018↗
  22. Prediction of R Status in Resections for Pancreatic Cancer Using Simplified Radiological Criteria: Not So Simple. First author DOI 10.1097/sla.0000000000005504↗
  23. Alterations in Somatic Driver Genes Are Associated with Response to Neoadjuvant FOLFIRINOX in Patients with Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/xcs.0000000000000212↗
  24. Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Treatment Does Not Predict Pathological Response and Survival in Resectable Pancreatic Ductal Adeno… Co-author DOI 10.1177/0003134821989050↗
  25. Recurrence After Resection of Pancreatic Cancer: Can Radiomics Predict Patients at Greatest Risk of Liver Metastasis? Last author DOI 10.1245/s10434-022-11579-0↗
  26. ASO Author Reflections: Predicting Pancreatic Cancer Liver Metastasis by Integrating Primary Tumor Clinicopathologic Features and Liver Radiomics. First author DOI 10.1245/s10434-022-11653-7↗
  27. Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study. Co-author DOI 10.6004/jnccn.2022.7008↗
  28. Treatment patterns and survival in patients with early-onset pancreatic cancer. Co-author DOI 10.1002/cncr.33664↗
  29. Preoperative CT predictors of survival in patients with pancreatic ductal adenocarcinoma undergoing curative intent surgery. Co-author DOI 10.1007/s00261-020-02726-w↗
  30. Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement. Co-author DOI 10.1097/sla.0000000000005080↗
  31. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cncr.33038↗
  32. CT radiomics associations with genotype and stromal content in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00261-019-02112-1↗
  33. Can physician gestalt predict survival in patients with resectable pancreatic adenocarcinoma? Co-author DOI 10.1007/s00261-017-1407-x↗
  34. The clinical utility of immunoglobulin G4 in the evaluation of autoimmune pancreatitis and pancreatic adenocarcinoma. Co-author DOI 10.1016/j.hpb.2017.09.001↗
  35. Extracellular matrix proteins and carcinoembryonic antigen-related cell adhesion molecules characterize pancreatic duct fluid exosomes in patients with pancrea… Last author DOI 10.1016/j.hpb.2017.12.010↗
  36. Survival Prediction in Pancreatic Ductal Adenocarcinoma by Quantitative Computed Tomography Image Analysis. Co-author DOI 10.1245/s10434-017-6323-3↗
  37. Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. Co-author DOI 10.1158/1078-0432.ccr-17-0899↗
  38. Percutaneous Peritoneal Lavage for the Rapid Staging of Gastric and Pancreatic Cancer. Co-author DOI 10.1245/s10434-016-5757-3↗
  39. Postoperative complications and overall survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.24125↗
  40. A Pilot Study Evaluating Serum MMP7 as a Preoperative Prognostic Marker for Pancreatic Ductal Adenocarcinoma Patients. Co-author DOI 10.1007/s11605-015-3057-z↗
  41. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Co-author DOI 10.1038/ncb3169↗
  42. FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-015-4647-4↗
  43. Hepatic arterial nodal metastases in pancreatic cancer: is this the node of importance? Co-author DOI 10.1007/s11605-012-2071-7↗
  44. Does pre-operative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase post-operative morbidity? A case-match… Co-author DOI 10.1111/hpb.12033↗
  45. Operative procedures for unresectable pancreatic cancer: does operative bypass decrease requirements for postoperative procedures and in-hospital days? Co-author DOI 10.1111/j.1477-2574.2012.00477.x↗
  46. Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Co-author DOI 10.1245/s10434-011-1900-3↗
  47. Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease. Co-author DOI 10.1245/s10434-011-2156-7↗
  48. Impact of obesity and body fat distribution on survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Co-author DOI 10.1245/s10434-012-2301-y↗
  49. A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. Co-author DOI 10.1371/journal.pone.0040157↗
  50. A case of synchronous pancreatic ductal adenocarcinoma and ovarian mucinous cystic neoplasm: use of kras mutation molecular phenotyping to demonstrate independ… Co-author PMID 22690261↗

Trials 1

  1. Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer Principal investigator NCT02393703↗

Closest collaborators

The 25 strongest of 152 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alice Chia-Chi Wei · 22 shared papers, 2021–2026 · strength 3.81
  2. Michael Ian D'Angelica · 35 shared papers, 2011–2026 · strength 3.79
  3. Jeffrey A. Drebin · 20 shared papers, 2019–2026 · strength 3.07
  4. Eileen Mary O'Reilly · 23 shared papers, 2012–2026 · strength 2.91
  5. T. Peter Kingham · 26 shared papers, 2012–2025 · strength 2.73
  6. Vinod P. Balachandran · 20 shared papers, 2017–2026 · strength 2.70
  7. Kevin C. Soares · 14 shared papers, 2021–2026 · strength 2.42
  8. Anna M. Varghese · 12 shared papers, 2017–2026 · strength 1.73
  9. Wungki Park · 9 shared papers, 2020–2026 · strength 1.43
  10. Peter J. Allen · 22 shared papers, 2011–2022 · strength 1.25
  11. Christopher H. Crane · 7 shared papers, 2021–2026 · strength 1.16
  12. Kenneth H. Yu · 8 shared papers, 2017–2026 · strength 1.10
  13. Caitlin A. McIntyre · 8 shared papers, 2019–2025 · strength 1.00
  14. Marsha Reyngold · 5 shared papers, 2021–2026 · strength 0.85
  15. T. Peter Kingham · 4 shared papers, 2025–2026 · strength 0.84
  16. Quisette P. Janssen · 5 shared papers, 2022–2023 · strength 0.68
  17. Richard Kinh Gian · 7 shared papers, 2015–2023 · strength 0.67
  18. Jayasree Chakraborty · 5 shared papers, 2018–2025 · strength 0.66
  19. Christine A. Iacobuzio–Donahue · 6 shared papers, 2017–2025 · strength 0.63
  20. Brett Logan Ecker · 4 shared papers, 2022–2024 · strength 0.62
  21. Fiyinfolu O. Balogun · 3 shared papers, 2025–2026 · strength 0.56
  22. David Paul Kelsen · 4 shared papers, 2020–2025 · strength 0.54
  23. Marinela Capanu · 4 shared papers, 2020–2025 · strength 0.53
  24. Constantinos Pantelis Zambirinis · 3 shared papers, 2018–2022 · strength 0.52
  25. Olca Baştürk · 5 shared papers, 2017–2025 · strength 0.51

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.